Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials

Manoj Maniar, PhD, Chen Ren, PhD, Patrick S. Zbyszewski, MBA, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, David Taft, PhD

Blood (2018) 132 (Supplement 1): 3106.

https://doi.org/10.1182/blood-2018-99-116982

Published: 2018

Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 230.

https://doi.org/10.1182/blood-2018-99-119259

Published: 2018

Journal Articles

Long Term Responses to Rigosertib in Lower-Risk Myelodysplastic Syndromes (MDS) Patients

Azra Raza, MD, Can Yalçın, Miray Cimist, Ryan Shelton, BS, Syed Fazl Ali Bilgrami, MD, Mark Lawrence Heaney, MD PhD, Abdullah Mahmood Ali, PhD

Blood (2017) 130 (Supplement 1): 5316.

https://doi.org/10.1182/blood.V130.Suppl_1.5316.5316

Published: 2017

Journal Articles

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Wojciech Jurczak, Simon Rule, MD, William Townsend, David Tucker, Martin Dyroff, Barbara Sarholz, Jürgen Scheele, John G. Gribben, MDDSc FMedSci, Pier Luigi Zinzani, MD

Blood (2017) 130 (Supplement 1): 2778.

https://doi.org/10.1182/blood.V130.Suppl_1.2778.2778

Published: 2017

Journal Articles

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Azra Raza, MD, Aref Al-Kali, MD, Raoul Tibes, MD PhD, Gary Spitzer, MD, Manila Gaddh, MD, Benjamin Tycko, MD PhD, Sangmin Lee, MD, Naomi Galili, PhD, Abdullah Mahmood Ali, PhD, John G. Mears, MD, Siddhartha Mukherjee, MD PhD, Ryan Shelton, BS, Steven M. Fruchtman, MD, Michael E. Petrone, MD MPH, Patrick S. Zbyszewski, MBA, Mark Lawrence Heaney, MD PhD

Blood (2017) 130 (Supplement 1): 1689.

https://doi.org/10.1182/blood.V130.Suppl_1.1689.1689

Published: 2017

Journal Articles

Idarucizumab for Reversing Anticoagulation in Patients Treated with Dabigatran: Experience in Our Center

Estefania Morente Constatin, MDCINE Resident, Marta Rivas Luque, Pablo Romero Garcia, MDCINE Resident, Maria Almudena Garcia-Ruiz, Manuel Jurado, MD PhD

Blood (2017) 130 (Supplement 1): 4923.

https://doi.org/10.1182/blood.V130.Suppl_1.4923.4923

Published: 2017

Journal Articles

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Pierre Fenaux, MD PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 3167.

https://doi.org/10.1182/blood.V128.22.3167.3167

Published: 2016

Journal Articles

Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, MD, Pierre Fenaux, MD PhD, Aref Al-Kali, MD, Shyamala C. Navada, MD, Maria R. Baer, MD, Azra Raza, MD, Peter Greenberg, MD, Karl-Anton Kreuzer, MD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Gail J. Roboz, Valeria Santini, MD, Uwe Platzbecker, MD, Michael E. Petrone, MD MPH, Bernard Brownstein, MD, Patrick Simon Zbyszewski, MBA, Manoj Maniar, PhD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 2011.

https://doi.org/10.1182/blood.V128.22.2011.2011

Published: 2016

Journal Articles

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Francois Wilhelm, MD PhD, Katherine Hearn, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D. DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Nozar Azarnia, PhD, Lewis R. Silverman, MD

Blood (2014) 124 (21): 3252.

https://doi.org/10.1182/blood.V124.21.3252.3252

Published: 2014

Journal Articles

BK Virus Hemorrhagic Cystitis Is Associated with Graft Versus Host Disease and Increased Health Care Resource Utilization in Patients Undergoing Allogeneic Stem Cell Transplantation

Wilson Lam, MD, Jan Storek, MD PhD, Nizar J Bahlis, MD, Christopher Brown, MD, Peter Duggan, MD FRCPC, Michelle Geddes, MD FRCPC, Mary Lynn Savoie, MD FRCPC, Mona Shafey, MD FRCPC, Douglas A. Stewart, MD FRCPC, Andrew Daly, MD FRCPC

Blood (2014) 124 (21): 3901.

https://doi.org/10.1182/blood.V124.21.3901.3901

Published: 2014

Journal Articles

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

Azra Raza, MD, Benjamin Tycko, M.D., Ph.D., Sangmin Lee, MD, Naomi Galili, Ph.D., Abdullah Ali, Andrew Eisenberger, MD, John G. Mears, MD, Aref Al-Kali, MD, Raoul Tibes, MD, PhD, Gary Spitzer, MD, Francois Wilhelm, MD, PhD., Siddhartha Mukherjee, MD, PhD

Blood (2013) 122 (21): 2745.

https://doi.org/10.1182/blood.V122.21.2745.2745

Published: 2013

Journal Articles

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, Erin P Demakos, RN, CCRN, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2013) 122 (21): 1527.

https://doi.org/10.1182/blood.V122.21.1527.1527

Published: 2013

Journal Articles

BK Virus Disease Following Allogeneic Stem Cell Transplantation: A Cohort Analysis

Nienke MG Rorije, Margaret M Shea, Gowri Satyanarayana, MD, Sarah P Hammond, MD, Vincent T Ho, MD, Lindsey R Baden, MD, Joseph H Antin, MD, Robert J Soiffer, MD, Francisco M Marty, MD

Blood (2012) 120 (21): 1927.

https://doi.org/10.1182/blood.V120.21.1927.1927

Published: 2012

Journal Articles

BK Virus Reactivation After Double Umbilical Cord Blood Transplantation in Adults Correlates with Tregs and Delayed Reconstitution of CD4 + and CD8 + T Effector Cells

Gowri Satyanarayana, MD, Sarah Hammond, MD, Haesook T Kim, PhD, Sean McDonough, MS, Julia Brown, PhD, Ioannis Politikos, MD, Lequn Li, MD, PhD, Raphael Viscidi, MD, Thomas Broge, Igor Koralnik, MD, Corey Cutler, MD, MPH, FRCPC, Karen K. Ballen, MD, Joseph H. Antin, MD, Francisco M Marty, MD, Jerome Ritz, MD, C Sabrina Tan, MD, Vassiliki A. Boussiotis, MD, PhD

Blood (2012) 120 (21): 4174.

https://doi.org/10.1182/blood.V120.21.4174.4174

Published: 2012

Journal Articles

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2012) 120 (21): 3794.

https://doi.org/10.1182/blood.V120.21.3794.3794

Published: 2012

Journal Articles

Oral Formulation of Rigosertib (ON 01910.Na) in Patients with Myelodysplastic Syndrome (MDS) – Phase I Study Results,

Rami S. Komrokji, MD, Alan F. List, MD, Francois Wilhelm, MD, PhD., Jeffrey E. Lancet, MD, Azra Raza, MD

Blood (2011) 118 (21): 3797.

https://doi.org/10.1182/blood.V118.21.3797.3797

Published: 2011

Journal Articles

Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting

Devi D Morrison, Samith Thomas Kochuparambil, David Deremer, Ethan Speir, Kristen Sterling, Meghan Sterrett, Vamsi Kota, MBBS, Anand P. Jillella, MD, Farrukh T Awan, MD, MS

Blood (2011) 118 (21): 4468.

https://doi.org/10.1182/blood.V118.21.4468.4468

Published: 2011

Journal Articles

Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study

Lewis R Silverman, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Vesna Najfeld, PhD, Takao Ohnuma, MD, Francois Wilhelm, MD, PhD., E. Premkumar Reddy, Ph.D., James F. Holland, MD

Blood (2010) 116 (21): 2944.

https://doi.org/10.1182/blood.V116.21.2944.2944

Published: 2010

Journal Articles

Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na

Mahesh Seetharam, MD, Mai Tran, Alice C. Fan, MD, Liwen Xu, PhD, John P. Renschler, Dean W. Felsher, MD, PhD, Kunju Sridhar, PhD, Francois Wilhelm, MD, PhD., Peter L. Greenberg, MD

Blood (2010) 116 (21): 4010.

https://doi.org/10.1182/blood.V116.21.4010.4010

Published: 2010

Journal Articles

Urinary Tract Infection In Immunocompromised Children Under Chemotherapy

Ye Jee Shim, M.D., Kun Soo Lee, M.D., Hyo Seop Ahn, Tai Ju Hwang, Hwi-Joong Yoon, MD, PhD

Blood (2010) 116 (21): 4765.

https://doi.org/10.1182/blood.V116.21.4765.4765

Published: 2010

NARROW

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Long Term Responses to Rigosertib in Lower-Risk Myelodysplastic Syndromes (MDS) Patients

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Idarucizumab for Reversing Anticoagulation in Patients Treated with Dabigatran: Experience in Our Center

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

BK Virus Hemorrhagic Cystitis Is Associated with Graft Versus Host Disease and Increased Health Care Resource Utilization in Patients Undergoing Allogeneic Stem Cell Transplantation

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

BK Virus Disease Following Allogeneic Stem Cell Transplantation: A Cohort Analysis

BK Virus Reactivation After Double Umbilical Cord Blood Transplantation in Adults Correlates with Tregs and Delayed Reconstitution of CD4 + and CD8 + T Effector Cells

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

Oral Formulation of Rigosertib (ON 01910.Na) in Patients with Myelodysplastic Syndrome (MDS) – Phase I Study Results,

Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting

Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study

Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na

Urinary Tract Infection In Immunocompromised Children Under Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only